Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics' stock price has increased significantly in the past six months. In March 2026, the stock jumped due to a new clinical collaboration with Erasca. The company reported strong growth in collaboration revenue for full-year 2025. Tango Therapeutics has received a "Strong Buy" consensus rating from Wall Street analysts. The company is on track to initiate a pivotal study for vopimetostat monotherapy and anticipates encouraging early efficacy data for the vopimetostat plus RAS(ON) inhibitors combination study in 2026. A strategic collaboration with Gilead Sciences enhances development capabilities.

Tango Therapeutics' products and services do not exhibit traditional demand seasonality. Demand for its pipeline products is driven by the progression of clinical trials, regulatory milestones, and unmet medical needs in specific cancer patient populations. The company's revenue is primarily generated through collaborations and partnerships rather than direct sales, so demand is not seasonal in the conventional sense.

Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company focused on discovering and developing precision medicines for cancer. The company leverages synthetic lethality and a CRISPR-based target discovery engine to identify and validate novel drug targets for genetically defined cancers. Its pipeline includes small-molecule cancer therapeutics, with leading programs being methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors like TNG462 and TNG456. The company is also developing TNG908, a synthetic lethal small molecule inhibitor of PRMT5, and inhibitors for BRCA1 and BRCA2-mutant cancers, as well as therapies targeting STK11-mutant cancers, including TNG260.

Tango Therapeutics is headquartered in Cambridge, Massachusetts, a biotechnology hub. Its primary operations, including research, development, and corporate activities, are based in the United States. While it does not have significant physical operations outside the U.S., its development programs and collaborations provide an indirect international presence through global clinical trial enrollment and partnerships.

Tango Therapeutics has maintained a generally positive brand reputation over the past year, driven by strong clinical progress and investor confidence. Positive sentiment is fueled by strong clinical data from vopimetostat trials, substantial financing, and analyst upgrades. Strategic collaborations and a solid cash position have contributed to a positive outlook. Management's participation in major healthcare conferences helps to disseminate positive updates and maintain visibility.

Tango Therapeutics, Inc. has a significant institutional ownership presence. Institutional ownership is high, placing it in the top 30% of all stocks. Ecor1 Capital LLC is the largest individual shareholder. Insider selling has been observed in the past three months.